These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23738395)

  • 1. The end of insulin? A newly discovered hormone could free diabetics from injections.
    Park A
    Time; 2013 May; 181(18):12. PubMed ID: 23738395
    [No Abstract]   [Full Text] [Related]  

  • 2. Postprandial insulin secretion after gastric bypass surgery: the role of glucagon-like peptide 1.
    Holst JJ
    Diabetes; 2011 Sep; 60(9):2203-5. PubMed ID: 21868790
    [No Abstract]   [Full Text] [Related]  

  • 3. Intensive insulin therapy in newly diagnosed type 2 diabetes.
    Retnakaran R; Drucker DJ
    Lancet; 2008 May; 371(9626):1725-6. PubMed ID: 18502278
    [No Abstract]   [Full Text] [Related]  

  • 4. [The role of incretins. Type 2 diabetes with new beginnings].
    MMW Fortschr Med; 2005 Mar; 147(10):48-9. PubMed ID: 15803785
    [No Abstract]   [Full Text] [Related]  

  • 5. Early use of insulin for beta cell preservation.
    Kumar A
    J Assoc Physicians India; 2007 Jul; 55 Suppl():26-8. PubMed ID: 17927008
    [No Abstract]   [Full Text] [Related]  

  • 6. [New strategy in type 2 diabetes tested in clinical trials. Glucagon-like peptide 1 (GLP-1) affects basic caused of the disease].
    Ahrén B
    Lakartidningen; 2005 Feb 21-27; 102(8):545-9. PubMed ID: 15786905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect and mechanism of transient continuous subcutaneous insulin infusion therapy on beta cell function, insulin resistance and vascular endothelial injury in newly diagnosed type 2 diabetes].
    Liu SP; Mo H; Liu BL; Tang WL; Deng XG; Su X; Yao L; Lin J; Feng Q; Peng J; Zhou ZG; Li YJ
    Zhonghua Nei Ke Za Zhi; 2010 May; 49(5):405-9. PubMed ID: 20646415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pancreatic pacemaker out of rhythm. Disturbed pulsatile insulin release therapeutically interesting in type 2 diabetes].
    Sjöholm A
    Lakartidningen; 2007 Aug 8-21; 104(32-33):2228-9. PubMed ID: 17822199
    [No Abstract]   [Full Text] [Related]  

  • 9. Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps.
    Weng J; Retnakaran R; Ariachery C A; Ji L; Meneghini L; Yang W; Woo JT
    Diabetes Metab Res Rev; 2015 Sep; 31(6):537-44. PubMed ID: 25196375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment.
    Takabe M; Matsuda T; Hirota Y; Hashimoto N; Nakamura T; Sakaguchi K; Ogawa W; Seino S
    Diabetes Res Clin Pract; 2012 Dec; 98(3):e32-5. PubMed ID: 23068961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [From insulin secretion to insulin therapy].
    Soltani D; Perlemuter L
    Presse Med; 1998 Jul 4-11; 27(24):1240-6. PubMed ID: 9767787
    [No Abstract]   [Full Text] [Related]  

  • 12. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
    Lam NT; Kieffer TJ
    Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Keeping the patient perspective: Where are we in the world of type 1 diabetes?
    Pettus J; von Herrath M
    Clin Immunol; 2013 Dec; 149(3):265-7. PubMed ID: 24012473
    [No Abstract]   [Full Text] [Related]  

  • 14. HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not?
    Reaven GM
    Diab Vasc Dis Res; 2009 Apr; 6(2):133-8. PubMed ID: 20368203
    [No Abstract]   [Full Text] [Related]  

  • 15. β-Cell signalling and insulin secretagogues: A path for improved diabetes therapy.
    Seino S; Sugawara K; Yokoi N; Takahashi H
    Diabetes Obes Metab; 2017 Sep; 19 Suppl 1():22-29. PubMed ID: 28880474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exenatide and biotin in conjunction with a protein-sparing fast for normalization of beta cell function in type 2 diabetics.
    McCarty MF
    Med Hypotheses; 2007; 69(4):928-32. PubMed ID: 17292559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Beta-cell function in the foreground. GLP-1 based therapy of type 2 diabetes].
    Kern W
    MMW Fortschr Med; 2010 Jan; 151 Suppl 4():173-8. PubMed ID: 21595145
    [No Abstract]   [Full Text] [Related]  

  • 18. [A therapeutic option for type-2 diabetes. The incretion hormone GLP-1].
    Göke B; Hoppe B; Konrad A; Schirra J
    Pharm Unserer Zeit; 2002; 31(3):294-9. PubMed ID: 12071126
    [No Abstract]   [Full Text] [Related]  

  • 19. Research advances in the treatment of type 2 diabetes mellitus.
    Caro J; Wishner KL
    Int J Clin Pract Suppl; 1999 Sep; 107():23-33. PubMed ID: 10692729
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
    Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
    Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.